Zynex: Order Growth, Already At +140%, Is Set To Accelerate
Order growth, and with it revenue growth, will accelerate again after already raking up a 140% growth in Q1. Salesforce productivity has a lot of upside; with hiring slowing down […]
Zynex Has Fallen Way Too Deep
Shares have been taken down yet again, on a mild guidance decrease. However, order growth has come back strongly and revenues will follow that. More especially, hiring will slow markedly […]
Zynex Is A Winner
The company is rapidly filling the void left by competitors in the subscription pain management device market. It is hiring sales representatives left, right and center, but it is still […]
Zynex Breaks Out With The Flywheel Effect Yet To Come
The company basks in device orders growing at 30% sequentially and 95% y/y. Revenue will follow more slowly, but ultimately much more pronounced as the company gets 80% of revenue […]
Bull Thesis In Zynex Confirmed By Q2 Figures
The company produced stellar Q2 figures despite a rather epic sales force ramp that took S&M 111% higher in the quarter. The company can easily afford this sales ramp, and […]
The Zynex Party Has Much Further To Go
The medical device company sprouts SaaS-like metrics; 30%+ growth, 80% recurring revenues, 80%+ gross margin and it’s profitable and cash flow positive. The big sales force expansion depress these figures […]